Lumacaftor/Ivacaftor Population Pharmacokinetics in Pediatric Patients with Cystic Fibrosis: A First Step Toward Personalized Therapy

Conclusions This study is the first analysis of lumacaftor/ivacaftor PPK in children with CF. These data suggest that dose adjustment is required after identifying variability factors to optimize efficacy. The use of therapeutic drug monitoring as a basis for dose adjustment in children with CF may be useful.

http://rd.springer.com/10.1007/s40262-023-01342-3

Source: Clinical Pharmacokinetics - February 4, 2024 Category: Drugs & Pharmacology Source Type: research